MedtechLedger currently links 19 FDA records to the applicant name Agilent Technologies, Inc.. It includes 5 original PMA approvals. 6 entries are PMA supplements. 8 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 2, 2015 to Sep 21, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Device categories in this collection
Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1; Immunohistochemistry Assay, Antibody, Melanoma-Associated Antigen A4; Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay; Immunohistochemistry Assay, Antibody, Ki-67.
Changes described in PMA records
The FDA recorded decision OK30 on 2026-09-21 for PMA supplement P150013/S034, submitted by Agilent Technologies, Inc. as a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement concerns PD-L1 IHC 22C3 pharmDx, an immunohistochemistry assay in the Pathology specialty under product code PLS. The recorded statement describes approval for a supplier's change to the manufacturing site for a device component.
This action covers only that supplier and manufacturing-site change within the existing P150013 approval; it is not a new approval of the assay as a whole. The source record does not identify the affected component, the supplier, the specific sites, or any supporting documents, and it gives no clinical or performance data. Whether the change affects labeling, analytical validation, or intended use cannot be determined from the available fields.
FDA approval-order wording
approval for a supplier's change to the manufacturing sight for a device component
Sep 21, 2026 · 30-Day NoticeThe FDA recorded decision OK30 on 2026-09-21 for MAGE-A4 IHC 1F9 pharmDx, filed under P230016/S004 by Agilent Technologies, Inc. The supplement is a 30-Day Notice with the recorded reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The statement describes approval for a supplier's change to the manufacturing site for a device component.
This action concerns a supplier and manufacturing-site change for a component of an immunohistochemistry antibody assay (product code SBL, Pathology), not a new approval of the assay itself. The source does not identify the affected component, the supplier, the prior or new manufacturing site, or any performance data supporting the change. Whether the approved change alters device labeling or clinical use is not stated and remains unknown from this record.
FDA approval-order wording
approval for a supplier's change to the manufacturing sight for a device component
Sep 21, 2026 · 30-Day NoticeThe FDA recorded decision OK30 on 2026-09-21 for PMA supplement P150025/S019, associated with PD-L1 IHC 28-8 pharmDx and submitted by Agilent Technologies, Inc. The supplement was filed as a 30-Day Notice under the reason category Process Change - Manufacturer/Sterilizer/Packager/Supplier. The recorded statement describes approval of a supplier's change to the manufacturing site for a device component.
This action concerns a manufacturing supply change for one component of the device rather than a new approval of the assay system as a whole. The source record does not identify the specific component, the supplier, the old or new manufacturing site, or any supporting documents, and it lists no device category or product code. The specialty field is Pathology. Whether the change carries clinical or analytical implications for assay performance is not stated in the available data.
The date shown is the recorded decision date in this source and should be verified against the FDA record before use in regulatory or compliance documentation. No patient-selection thresholds, testing instructions or performance claims are part of this supplement record.
FDA approval-order wording
approval for a supplier's change to the manufacturing sight for a device component
Sep 21, 2026 · 30-Day NoticeFDA’s recorded scope: MAGE-A4 IHC IF9 pharmDx is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, intended for use in the detection of MAGE-A4 protein in formalin-fixed, paraffin-embedded (FFPE) synovial sarcoma tissue using the EnVision FLEX visualization system on Autostainer Link 48. MAGE-A4 protein expression in synovial sarcoma is determined by using the MAGE-A4 Tumor Intensity Proportion Score (TIPS), which is the overall percentage of viable tumor cells showing MAGE-A4 nuclear and/or cytoplasmic staining at staining intensity = 2+. The specimen should be considered positive if MAGE-A4 TIPS (= 2+) is = 75%.MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA (afamitresgene autoleucel), a MAGE-A4-directed genetically modified autologous T-cell immunotherapy, is being considered.
Sep 15, 2026 · Normal 180 Day TrackThe FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-11 for supplement P150013/S035 to Agilent Technologies, Inc.'s PD-L1 IHC 22C3 pharmDx, an immunohistochemistry antibody assay for programmed death-ligand 1 under product code PLS in the pathology specialty. The recorded statement covers approval of manufacturing process and equipment changes for filling and capping.
This action concerns the manufacturing process rather than a new approval of the assay itself; the supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The source record does not identify which filling or capping equipment changed, the sites involved, or any supporting validation data, and no linked FDA documents are included. Whether the change affects assay performance or labeling cannot be determined from this record.
The decision date is in the future relative to typical publication timelines, and the record provides no clinical, analytical or legal detail beyond the fields shown. Readers should treat the scope as limited to the stated manufacturing change.
FDA approval-order wording
approval of manufacturing process and equipment changes for filling and capping
Sep 11, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.